GlobeNewswire·Nov 9, 2026, 7:00 AM ET

Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Phase 3 CoMpass trial for bel-sar in early choroidal melanoma is fully enrolled with 108 participants, all of whom have completed treatment visits.
The CoMpass trial is on track to deliver topline data from the 15-month primary endpoint in the second half of 2027.
The trial is conducted under a Special Protocol Assessment (SPA) agreement with the FDA to support a potential Biologics License Application.
Aura Biosciences established a relationship with an industry-leading CDMO to secure designated manufacturing capacity for bel-sar.
An investor and analyst virtual event regarding early choroidal melanoma is scheduled for December 8, 2026.
Aura expects its cash, cash equivalents, and marketable securities of $297.2 million to fund operations into the first half of 2029.
Research and development expenses for the three months ended September 30, 2026, were $24.7 million, up from $22.2 million in the prior year period.
General and administrative expenses increased to $10.3 million for the quarter ended September 30, 2026, driven by $4.5 million in restructuring charges.
Net loss for the three months ended September 30, 2026, was $32.1 million compared to $26.1 million in the same period of 2025.
CEO Natalie Holles will participate in the Stifel 2026 Healthcare Conference on November 10, 2026, & the 9th Annual Evercore Healthcare Conference on December 1, 2026.